Current pharmacologic drugs that are used to treat osteoporosis mainly aim to reduce excessive bone resorption (e.g. estrogen and bisphosphonates) or promote bone formation (e.g. parathyroid hormone (PTH)), and to a lesser degree a combination of both (e.g. anti-sclerostin antibody) [5]. This evidence concerns the gene PTH and osteoporosis.